Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ligand Pharmaceuticals Inc. (NASDAQ: LGND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Ligand’s royalty‑focused biopharmaceutical business, financing activities and material agreements that support its model of funding mid‑ to late‑stage drug development, purchasing royalty rights and licensing technology platforms.
Ligand’s recent 8‑K filings describe events such as the completion of a private offering of 0.75% convertible senior notes due 2030, amendments to its credit agreement with Citibank, N.A., and the entry into material definitive agreements. Other 8‑Ks report quarterly financial results, including revenue composition and non‑GAAP measures, and discuss transactions like royalty financing agreements and the closing of a merger involving a Ligand subsidiary that became part of Pelthos Therapeutics. Filings also confirm that Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND and identify Jupiter, Florida as the location of its principal executive offices.
On Stock Titan, these SEC filings are paired with AI‑powered summaries designed to make complex regulatory language more accessible. Annual reports on Form 10‑K and quarterly reports on Form 10‑Q can be reviewed for discussions of Ligand’s business model, risk factors and segment information, while current reports on Form 8‑K highlight specific material events such as financings, credit facility amendments and significant portfolio transactions. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers.
Real‑time updates from EDGAR ensure that new LGND filings appear promptly, and AI analysis helps explain how each document relates to Ligand’s strategy of building diversified royalty and technology revenue streams. This combination allows investors and researchers to move efficiently from raw filings to a clearer understanding of the company’s regulatory and financial disclosures.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.
Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.
Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.
The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.
LGND reported a proposed sale of common stock on a Form 144 with transactions dated
Ligand Pharmaceuticals filed a Form S-3 shelf registration to offer up to
Ligand Pharmaceuticals Incorporated presents its annual report describing a royalty-focused biopharmaceutical business model built around capital deployment and licensing rather than in‑house drug development. The company aggregates royalty interests in mid‑ to late‑stage and commercial products, supported by infrastructure‑light platforms such as Captisol and NITRICIL.
Ligand highlights 12 major commercial royalty assets and more than 100 additional partnered programs, with 2025 royalty receipts of $176.9 million and GAAP income from royalty assets of $161.0 million. Key assets include Kyprolis, Qarziba, Filspari, Ohtuvayre, Capvaxive, Vaxneuvance, Rylaze, Evomela and Zelsuvmi.
During 2025, Ligand executed several investments and strategic transactions, including royalty financings with Castle Creek and Orchestra BioMed, a royalty and warrant deal with Arecor, and the Pelthos Transaction, which spun out Zelsuvmi into Pelthos Therapeutics while retaining equity, milestones and a 13% royalty. As of February 24, 2026, Ligand had 19,941,141 common shares outstanding.